709 related articles for article (PubMed ID: 28400446)
1. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.
Jayne DRW; Bruchfeld AN; Harper L; Schaier M; Venning MC; Hamilton P; Burst V; Grundmann F; Jadoul M; Szombati I; Tesař V; Segelmark M; Potarca A; Schall TJ; Bekker P;
J Am Soc Nephrol; 2017 Sep; 28(9):2756-2767. PubMed ID: 28400446
[TBL] [Abstract][Full Text] [Related]
2. Avacopan for the Treatment of ANCA-Associated Vasculitis.
Jayne DRW; Merkel PA; Schall TJ; Bekker P;
N Engl J Med; 2021 Feb; 384(7):599-609. PubMed ID: 33596356
[TBL] [Abstract][Full Text] [Related]
3. Avacopan in the treatment of ANCA-associated vasculitis.
Tesar V; Hruskova Z
Expert Opin Investig Drugs; 2018 May; 27(5):491-496. PubMed ID: 29718732
[TBL] [Abstract][Full Text] [Related]
4. Avacopan, a selective C5a receptor antagonist, for anti-neutrophil cytoplasmic antibody-associated vasculitis.
Harigai M; Takada H
Mod Rheumatol; 2022 Apr; 32(3):475-483. PubMed ID: 34984461
[TBL] [Abstract][Full Text] [Related]
5. Glucocorticoid Toxicity Index scores by domain in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with avacopan versus standard prednisone taper: post-hoc analysis of data from the ADVOCATE trial.
Patel NJ; Jayne DRW; Merkel PA; Bekker P; Zhang Y; Yue H; Stone JH
Lancet Rheumatol; 2023 Mar; 5(3):e130-e138. PubMed ID: 38251609
[TBL] [Abstract][Full Text] [Related]
6. Avacopan: First Approval.
Lee A
Drugs; 2022 Jan; 82(1):79-85. PubMed ID: 34826105
[TBL] [Abstract][Full Text] [Related]
7. Journal Club Review of "Avacopan for the Treatment of ANCA-Associated Vasculitis".
Soulsby WD
ACR Open Rheumatol; 2022 Jul; 4(7):558-561. PubMed ID: 35167187
[TBL] [Abstract][Full Text] [Related]
8. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial.
Strand V; Jayne DRW; Horomanski A; Yue H; Bekker P; Merkel PA;
Lancet Rheumatol; 2023 Aug; 5(8):e451-e460. PubMed ID: 38251577
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial.
Geetha D; Dua A; Yue H; Springer J; Salvarani C; Jayne D; Merkel P;
Ann Rheum Dis; 2024 Jan; 83(2):223-232. PubMed ID: 37979959
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial.
Merkel PA; Jayne DR; Wang C; Hillson J; Bekker P
JMIR Res Protoc; 2020 Apr; 9(4):e16664. PubMed ID: 32088663
[TBL] [Abstract][Full Text] [Related]
11. New therapeutic strategies in lung vasculitis.
Nasser M; Cottin V
Curr Opin Pulm Med; 2020 Sep; 26(5):496-506. PubMed ID: 32740376
[TBL] [Abstract][Full Text] [Related]
12. Being an ADVOCATE for People with ANCA Vasculitis.
Anders HJ; Nakazawa D
Clin J Am Soc Nephrol; 2021 Oct; 16(10):1581-1583. PubMed ID: 34083218
[No Abstract] [Full Text] [Related]
13. Avacopan for the Treatment of Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis.
Alihosseini C; Kopelman H; Zaino M; Feldman SR
Ann Pharmacother; 2023 Dec; 57(12):1449-1454. PubMed ID: 36975183
[TBL] [Abstract][Full Text] [Related]
14. Renal improvement and remission in a patient with refractory ANCA-associated vasculitis treated with avacopan.
Alvarez L; Kambham N; Su R
J Nephrol; 2023 Nov; 36(8):2365-2370. PubMed ID: 37036661
[TBL] [Abstract][Full Text] [Related]
15. Complement inhibition in ANCA vasculitis.
Jayne D
Nephrol Ther; 2019 Nov; 15(6):409-412. PubMed ID: 31631015
[TBL] [Abstract][Full Text] [Related]
16. How the Availability of Anti-C5a Agents Could Change the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Roccatello D; Fenoglio R; Oddone V; Sciascia S
Kidney Blood Press Res; 2022; 47(8):506-513. PubMed ID: 35665698
[TBL] [Abstract][Full Text] [Related]
17. Vasculitis: A CLEAR argument for targeting complement in ANCA vasculitis.
Kettritz R
Nat Rev Nephrol; 2017 Aug; 13(8):448-450. PubMed ID: 28529340
[No Abstract] [Full Text] [Related]
18. Avacopan for the treatment of ANCA-associated vasculitis: an update.
Osman M; Cohen Tervaert JW; Pagnoux C
Expert Rev Clin Immunol; 2023 May; 19(5):461-471. PubMed ID: 36545762
[TBL] [Abstract][Full Text] [Related]
19. Reducing glucocorticoid duration in ANCA-associated vasculitis: A pilot trial.
Miloslavsky EM; Niles JL; Wallace ZS; Cortazar FB; Fernandes A; Laliberte K; Stone JH
Semin Arthritis Rheum; 2018 Oct; 48(2):288-292. PubMed ID: 29530330
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacological and clinical profiles of avacopan (TAVNEOS
Maruyama Y; Yoshida T; Maruyama I
Nihon Yakurigaku Zasshi; 2023 Sep; 158(5):399-407. PubMed ID: 37460300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
